Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan CED for Recurrent High Grade Glioma
NCT03193463Phase 1Withdrawn
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 1, open-label trial of topotecan liposome in high-grade glioma (HGG) (3 arms). Primary endpoints: Number of intra-operative catheter related complications up to 12 months, Number of post-operative catheter related complications up to 12 months and 2 more. Planned start Nov 2017; status: withdrawn.
02
Drugs
topotecan liposome
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03193463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193463.